Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Warfarin × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 4 Genitourinary 3 Classical hematology 3 Other solid neoplasm 2 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 Lymphoid 1 Gynecologic 1 Gastrointestinal 1

Conditions

Neoplasms, Plasma Cell 1 Multiple Myeloma 1

Interventions

Dexamethasone 764 Lenalidomide 405 Bortezomib 402 Cyclophosphamide 330 Melphalan 252 Calcium Dobesilate 229 daratumumab 204 pomalidomide 177 carfilzomib 154 fludarabine 122 fludarabine phosphate 117 Thalidomide 110 Peripheral Blood Stem Cell Transplantation 108 Filgrastim 103 ixazomib 85 Whole-Body Irradiation 80 Mycophenolic Acid 77 dexamethasone acetate 76 Granulocyte Colony-Stimulating Factor 76 Busulfan 75 Tacrolimus 66 dexamethasone 21-phosphate 63 Prednisone 59 Cyclosporine 59 auricularum 58 isatuximab 54 belantamab mafodotin 53 Antilymphocyte Serum 50 elotuzumab 49 Radiotherapy 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00790842 2018-10-24

PrE1003

PrECOG, LLC.

Phase 1/2 Terminated

63 enrolled 14 charts

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡